BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 7, 2026
Breaking News: BioWorld Science 2025 Year in Review
See today's BioWorld Science
Home
» Hepagene Therapeutics patents new HBV antivirals
To read the full story,
subscribe
or
sign in
.
Infection
Hepagene Therapeutics patents new HBV antivirals
Aug. 30, 2022
Hepagene Therapeutics Inc. has divulged compounds reported to be useful for the treatment of hepatitis B virus (HBV) infections.
BioWorld Science
Infection
Patents